SIC
ALDX icon

SJS Investment Consulting’s Aldeyra Therapeutics ALDX Stock Holding History

SJS Investment Consulting’s Portfolio ALDX Stock Details ALDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$405 Sell
190
-94
-33% -$162 ﹤0.01% 2327
2026
Q1 		$480 Buy
284
+270
+1,929% +$1.18K ﹤0.01% 1752
2025
Q4 		$73 Buy
+14
New +$72 ﹤0.01% 1983

Other funds holding ALDX

KCM
Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
D.E. Shaw & Co
D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $108B AUM 37.29% 1-Year Est. Return

SJS Investment Consulting's ALDX Position: Q2 2026 in Review

SJS Investment Consulting reduced its Aldeyra Therapeutics (ALDX) stake by 33% in Q2 2026, selling an estimated $162 and leaving 190 shares worth $405. The position accounts for ﹤0.01% of the portfolio, ranked #2327.

SJS Investment Consulting first reported a position in ALDX in Q4 2025 and has held it in 3 quarters since. The position peaked at $480 in Q1 2026. 108 funds tracked by Wall St. Rank hold ALDX as of Q2 2026.

  • SJS Investment Consulting held 190 shares of Aldeyra Therapeutics worth $405 as of Q2 2026.
  • SJS Investment Consulting sold 94 Aldeyra Therapeutics shares in Q2 2026, an estimated $162.
  • Aldeyra Therapeutics made up ﹤0.01% of SJS Investment Consulting's portfolio in Q2 2026, its #2327 holding.
  • SJS Investment Consulting first reported a position in Aldeyra Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • SJS Investment Consulting's Aldeyra Therapeutics position peaked at $480 in Q1 2026.
  • 108 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q2 2026.

Based on SJS Investment Consulting's 13F filing for Q2 2026, filed 22 Jul 2026.